AbbVie Inc (ABBV)vsANI Pharmaceuticals Inc (ANIP)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
ANIP
ANI Pharmaceuticals Inc
$70.19
-1.78%
HEALTHCARE · Cap: $1.64B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 6481% more annual revenue ($64.39B vs $978.38M). ANIP leads profitability with a 11.1% profit margin vs 9.8%. ABBV appears more attractively valued with a PEG of 0.52. ANIP earns a higher WallStSmart Score of 76/100 (B+).
ABBV
Strong Buy73
out of 100
Grade: B
ANIP
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for ANIP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 191.1% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 25.9% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : ANIP
The strongest argument for ANIP centers on EPS Growth, P/E Ratio, Price/Book. Revenue growth of 25.9% demonstrates continued momentum. PEG of 1.06 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : ANIP
The primary concerns for ANIP are Altman Z-Score, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while ANIP is a growth play — different risk/reward profiles.
ANIP carries more volatility with a beta of 0.45 — expect wider price swings.
ANIP is growing revenue faster at 25.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ANIP scores higher overall (76/100 vs 73/100) and 25.9% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
ANI Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?